Failure of Cimetidine to Affect Calcium Homeostasis in Familial Primary Hyperparathyroidism (Multiple Endocrine Neoplasia, Type 1)*
- 1 October 1980
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 51 (4) , 912-914
- https://doi.org/10.1210/jcem-51-4-912
Abstract
Recent reports that cimetidine, a blocker of histamine H2 receptors, lowered serum calcium and/or immunoreactive parathyroid hormone (PTH) concentrations in primary or secondary hyperparathyroidism prompted us to administer the drug (300 mg, orally, every 6 h) to two patients with hyperparathyroidism accompanying familial multiple endocrine neoplasia type 1. The patients were hypercalcemic (10.9–11.2 mg/ dl), hypophosphatemic (2.0–2.4 mg/dl), and hypercalciuric (≥410 mg//24 h), with elevated urinary cAMP and phosphate clearance and inappropriately high serum immunoreactive PTH levels. Multiple observations of these variables over 5 weeks of cimetidine treatment showed no systematic changes; in particular, serum and urinary calcium did not change, and there was no evidence of a decreased PTH effect on the kidneys. The data offer no support for the treatment of familial hyperparathyroidism with cimetidine.Keywords
This publication has 0 references indexed in Scilit: